Alprostadil Pediatric Dose — Cardiovascular Infusions
Alprostadil (prostaglandin E₁, PGE₁) is a naturally occurring prostaglandin that acts on EP receptors to produce potent vasodilation of the ductus arteriosus. It is the cornerstone pharmacologic agent for stabilizing neonates and infants with ductal-dependent congenital heart lesions, maintaining patency of the ductus arteriosus until surgical or catheter-based intervention can be performed.
Pediatric Dosing
Alprostadil is administered as a continuous intravenous infusion at 0.01–0.1 mcg/kg/min. Therapy is typically initiated at the lower end of the range and titrated to clinical effect (improved oxygenation or systemic perfusion), using the lowest effective dose to minimize adverse effects.
- Starting dose: 0.01 mcg/kg/min IV infusion
- Titration range: up to 0.1 mcg/kg/min IV infusion based on response
Worked example — 3.5 kg neonate: At 0.01 mcg/kg/min: 3.5 × 0.01 = 0.035 mcg/min. At 0.1 mcg/kg/min: 3.5 × 0.1 = 0.35 mcg/min. Consult institutional pharmacy protocol for specific dilution and infusion pump programming guidance.
Indications and Clinical Context
Alprostadil is indicated for neonates with ductal-dependent congenital heart disease, including lesions that depend on right-to-left ductal flow (e.g., critical pulmonary stenosis or atresia, hypoplastic right heart) or left-to-right ductal flow (e.g., critical aortic stenosis, coarctation of the aorta, hypoplastic left heart syndrome). Maintaining ductal patency is life-saving in these conditions pending definitive intervention. Early initiation — often guided by clinical suspicion prior to echocardiographic confirmation — is consistent with standard neonatal and PALS resuscitation principles for ductal-dependent lesion management.
Alprostadil may also be considered when a neonate presents with unexplained cyanosis, metabolic acidosis, or shock refractory to fluid resuscitation, where a ductal-dependent lesion remains on the differential diagnosis.
Administration and Monitoring
Alprostadil must be administered as a continuous IV infusion via a dedicated lumen, preferably through a central venous catheter; peripheral IV access may be used temporarily if central access is unavailable. The infusion should never be given as a bolus. Once clinical stabilization is achieved, the dose should be weaned to the lowest effective rate.
- Apnea: The most clinically significant adverse effect; occurs in approximately 10–12% of neonates, particularly those weighing less than 2 kg. Anticipate and prepare for airway management, including elective intubation in transport settings.
- Fever, cutaneous flushing, and hypotension are common dose-dependent effects; monitor vital signs continuously.
- Seizure-like activity and jitteriness have been reported; assess neurologic status regularly.
- Consult institutional protocol for dilution standards, compatible diluents, and infusion pump concentration programming.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.